| Hazard Information | Back Directory | [Clinical Use]
Monoclonal antibody:
Treatment of ulcerative colitis and Crohn’s disease | [Drug interactions]
Potentially hazardous interactions with other drugs
Live vaccines: risk of generalised infections - avoid. | [Metabolism]
The expected consequence of metabolism is proteolytic degradation to small peptides and individual amino acids, and receptor-mediated clearance. The exact elimination route of vedolizumab is unknown although renal clearance is expected to be negligible. |
|
|